Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients Shows Benefits in Phase 3 Trial

Stem Cell Therapy for Perianal Fistulas in Crohn’s Patients Shows Benefits in Phase 3 Trial
The 24-week results of a Phase 3 trial showing the effectiveness of the investigational therapy Cx601 in the treatment of complex perianal fistulas in patients with Crohn's disease were recently published in The Lancet, according to Takeda Pharmaceutical and TiGenix. The study is titled "Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial." Patients with Crohn's disease often exhibit complex
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *